Darolutamide
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Darolutamide |
| DrugBank ID | DB12941 |
| Brand Names (EU) | Nubeqa |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.11% |
Approved Indication (EMA)
NUBEQA is indicated for the treatment of adult men with non‑metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease (see section 5.1). metastatic hormone‑sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (see section 5.1). metastatic hormone‑sensitive prostate cancer (mHSPC) in combination with docetaxel and androgen deprivation therapy (see section 5.1).
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | homozygous familial hypercholesterolemia | 99.11% | DL |
| 2 | multiple endocrine neoplasia | 99.06% | DL |
| 3 | HIV infectious disease | 99.04% | DL |
| 4 | simian immunodeficiency virus infection | 98.70% | DL |
| 5 | feline acquired immunodeficiency syndrome | 98.70% | DL |
| 6 | neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter | 98.56% | DL |
| 7 | cytomegalovirus infection | 98.33% | DL |
| 8 | thrombotic disease | 98.29% | DL |
| 9 | malignant catarrh | 98.18% | DL |
| 10 | infectious bovine rhinotracheitis | 98.18% | DL |
| 11 | rheumatoid arthritis | 97.64% | DL |
| 12 | Prinzmetal angina | 97.57% | DL |
| 13 | hypoalphalipoproteinemia | 97.52% | DL |
| 14 | antithrombin deficiency type 2 | 97.38% | DL |
| 15 | heparin cofactor 2 deficiency | 97.29% | DL |
| 16 | hyperthyroidism | 97.27% | DL |
| 17 | factor 5 excess with spontaneous thrombosis | 97.14% | DL |
| 18 | resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta | 97.01% | DL |
| 19 | oral candidiasis | 96.75% | DL |
| 20 | leprosy | 96.70% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.